Martin Mackay - Net Worth and Insider Trading

Martin Mackay Net Worth

The estimated net worth of Martin Mackay is at least $10 Million dollars as of 2024-04-26. Martin Mackay is the EVP & Global Head of R&D of Alexion Pharmaceuticals Inc and owns about 50,688 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $9 Million. Martin Mackay is also the CEO of Rallybio Corp and owns about 719,126 shares of Rallybio Corp (RLYB) stock worth over $1 Million. Details can be seen in Martin Mackay's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Martin Mackay has not made any transactions after 2022-01-11 and currently still holds the listed stock(s).

Transaction Summary of Martin Mackay

To

Martin Mackay Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Mackay owns 5 companies in total, including 5:01 Acquisition Corp (FVAM) , Charles River Laboratories International Inc (CRL) , and Alexion Pharmaceuticals Inc (ALXN) among others .

Click here to see the complete history of Martin Mackay’s form 4 insider trades.

Insider Ownership Summary of Martin Mackay

Ticker Comapny Transaction Date Type of Owner
FVAM 5:01 Acquisition Corp 2020-10-13 director
CRL Charles River Laboratories International Inc 2017-07-01 director
ALXN Alexion Pharmaceuticals Inc 2017-03-01 EVP & Global Head of R&D
PFE Pfizer Inc 2007-10-04 Senior Vice President
RLYB Rallybio Corp 2022-01-11 director & Chief Executive Officer

Martin Mackay Latest Holdings Summary

Martin Mackay currently owns a total of 2 stocks. Among these stocks, Martin Mackay owns 50,688 shares of Alexion Pharmaceuticals Inc (ALXN) as of March 1, 2017, with a value of $9 Million and a weighting of 88.63%. Martin Mackay also owns 719,126 shares of Rallybio Corp (RLYB) as of January 11, 2022, with a value of $1 Million and a weighting of 11.37%.

Latest Holdings of Martin Mackay

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALXN Alexion Pharmaceuticals Inc 2017-03-01 50,688 182.50 9,250,560
RLYB Rallybio Corp 2022-01-11 719,126 1.65 1,186,558

Holding Weightings of Martin Mackay


Martin Mackay Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Mackay has made a total of 0 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years. The most-recent trade in Alexion Pharmaceuticals Inc is the sale of 1,855 shares on March 1, 2017, which brought Martin Mackay around $244,174.

According to the SEC Form 4 filings, Martin Mackay has made a total of 1 transactions in Rallybio Corp (RLYB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Rallybio Corp is the acquisition of 10,000 shares on January 11, 2022, which cost Martin Mackay around $103,500.

Insider Trading History of Martin Mackay

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Mackay Trading Performance

GuruFocus tracks the stock performance after each of Martin Mackay's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Martin Mackay is -24%. GuruFocus also compares Martin Mackay's trading performance to market benchmark return within the same time period. The performance of stocks bought by Martin Mackay within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Martin Mackay's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Martin Mackay

Average Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 29.1 -24 -25.21 -47.82 -57.82
Relative Return to S&P 500(%) 35.35 -17.62 -6.99 -32.05 -58.53

Martin Mackay Ownership Network

Ownership Network List of Martin Mackay

No Data

Ownership Network Relation of Martin Mackay


Martin Mackay Owned Company Details

What does 5:01 Acquisition Corp do?

Who are the key executives at 5:01 Acquisition Corp?

Martin Mackay is the director of 5:01 Acquisition Corp. Other key executives at 5:01 Acquisition Corp include director & 10 percent owner & Co-CEO Andrew J. Schwab , director & 10 percent owner & Co-CEO Kush Parmar , and 10 percent owner 5am Ventures Vi, L.p. .

5:01 Acquisition Corp (FVAM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of 5:01 Acquisition Corp (FVAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of 5:01 Acquisition Corp (FVAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

5:01 Acquisition Corp (FVAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

5:01 Acquisition Corp Insider Transactions

No Available Data

Martin Mackay Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Mackay. You might contact Martin Mackay via mailing address: Pfizer Inc Attn Corporate Secretary, 235 East 42nd Street, New York Ny 10017.

Discussions on Martin Mackay

No discussions yet.